Current Issue : July - September Volume : 2020 Issue Number : 3 Articles : 5 Articles
Nutraceuticals have gained lot of attention in the present-day world as it seems to promote potential benefits in several chronic ailments including neurodegeneration, antioxidant and several other diseases. Solid Lipid Nanoparticles (SLN) is alternative drug delivery system to colloidal drug delivery system such as liposome, lipid emulsions. In this present study the SLN loaded with nutraceutical, piperine has been formulated and evaluated for determining the characteristics. Piperine was prepared as SLN by emulsion technique under the high shear homogenizer at the speed of 20,000rpm for 5min. The prepared SLN were subjected to various evaluations such as particle size, encapsulation efficiency, drug content and invitro release studies. The results showed that the SLN loaded with piperine average size were found to be 130nm and the zeta potential results shown that there was a good size distribution of the particles. The encapsulation efficiency of piperine was 99.17%. The in vitro release was predominantly by diffusion phenomenon explained by korsmeyerpeppas followed Higuchiâ??s model. The stability studies are indicative that the prepared SLN were stable. The SLNs of nutraceutical drug piperine was undergone various characterization studies after being formulated with various types of lipids, surfactants and cosurfactants. From the invitro kinetic model the drug release profile of the formulation has been concluded that the formulation follows the higuchi model of diffusion. The results are evident that the average size of SLN may play a significant role in bioavailability enhancement. To conclude, SLN loaded piperine can be useful for studying its in vivo characteristics....
Dietary habits are crucially important to prevent the development of lifestyle-associated\ndiseases. Diets supplemented with chickpeas have numerous benefits and are known to improve body\nfat composition. The present study was undertaken to characterize two genetically and phenotypically\ndistinct accessions, MG_13 and PI358934, selected from a global chickpea collection. Rat hepatoma\nFaO cells treated with a mixture of free fatty acids (FFAs) (O/P) were used as an in vitro model of\nhepatic steatosis. In parallel, a high-fat diet (HFD) animal model was also established. In vitro\nand in vivo studies revealed that both chickpea accessions showed a significant antioxidant ability.\nHowever, only MG_13 reduced the lipid over-accumulation in steatotic FaO cells and in the liver\nof HFD fed mice. Moreover, mice fed with HFD + MG_13 displayed a lower level of glycemia and\naspartate aminotransferase (AST) than HFD mice. Interestingly, exposure to MG_13 prevented the\nphosphorylation of the inflammatory nuclear factor kappa beta (NF-kB) which is upregulated during\nHFD and known to be linked to obesity. To conclude, the comparison of the two distinct chickpea\naccessions revealed a beneficial effect only for the MG_13. These findings highlight the importance of\nstudies addressing the functional characterization of chickpea biodiversity and nutraceutical properties...
The aim of the present critical review is to summarize the available clinical evidence\nsupporting the use of some dietary supplements that have been shown to lower blood pressure in\nhypertensive pregnant women. A systematic search strategy was carried out to identify trials in\nMEDLINE (National Library of Medicine, Bethesda, Maryland, MD, USA; January 1980 to September\n2019) and the Cochrane Register of Controlled Trials (The Cochrane Collaboration, Oxford, UK). The\nterms â??nutraceuticalsâ??, â??dietary supplementsâ??, â??pregnancyâ??, â??pre-eclampsiaâ??, â??clinical trialâ??, and â??humanâ??\nwere incorporated into an electronic search strategy. The references of the identified studies and\nreview articles were reviewed to look for additional studies of interest. We preferably selected papers\nthat reported recent comprehensive reviews or meta-analysis, or original clinical trials of substances\nwith blood pressure-lowering or vascular protective effect in pregnancy. There is a relative body of\nevidence that supports the use of calcium, vitamin D, folic acid, and resveratrol in preventing the\ndevelopment of hypertensive disorders in pregnancy, and evidence supporting drug treatment too.\nFurther clinical research is advisable to identify the dosage and timing of the supplementation, the\ngroup of women that might benefit the most from this approach, and the nutraceuticals with the best\ncost-effectiveness and risk-benefit ratio for widespread use in clinical practice....
In this study, nutraceuticals based on antimicrobial ingredients (Artemisia absinthium water\nextract and essential oil (EO), Lactobacillus uvarum LUHS245 strain cultivated in a whey media, and\nblackcurrants juice (BCJ) preparation by-products were developed. In addition, two texture forming\nagents for nutraceutical preparations were tested (gelatin and agar). The developed nutraceutical\ningredients showed antimicrobial properties: Artemisia absinthium EO (concentration 0.1%) inhibited\nmethicillin-resistant Staphylococcus aureus, Enterococcus faecium, Bacillus cereus, Streptococcus mutans,\nStaphylococcus epidermidis, and Pasteurella multocida; LUHS245 strain inhibited 14 from the 15 tested\npathogenic strains; and BCP inhibited 13 from the 15 tested pathogenic strains. The best formulation\nconsisted of the Artemisia absinthium EO, LUHS245, and BCP immobilised in agar and this formulation\nshowed higher TPC content (by 2.1% higher), as well as higher overall acceptability (by 17.7% higher),\ncompared with the formulation prepared using gelatin....
Polycystic ovary syndrome (PCOS) is a complex disorder associated with ovarian dysfunction,\ninfertility, menstrual irregularity, and hormonal impairments. Over the last decade, several studies have\nshown that some PCOS women have insulin resistance (InsR) and hyperinsulinemia, apart from being\noverweight or obese. Therefore, a crucial clinical aspect is that PCOS patients might develop glucose\nintolerance and type 2 diabetes. Insulin-sensitizing drugs have been used as first-line treatment to\nimprove hyperinsulinemia inwomen with PCOS. Although reducing PCOS symptoms and signs, several\nused insulin-sensitizer drugs may induce side effects, which reduces compliance. D-chiro-inositol (DCI),\nwhich is a naturally occurring stereoisomer of inositol, has been classified as an insulin-sensitizer and\nseems to mitigate multiple InsR-related metabolic alterations in PCOS with a safe profile. However,\naccording to a multi-targeted design, the supplementation with DCI can be synergistically integrated\nby combining other potential insulin-sensitizing drugs and/or nutraceuticals. The literature provides\nthe initial support for using several unexplored nutraceutical interventions that may target relevant\nmetabolic abnormalities associated with InsR in PCOS. With a need to promote interest in clinical\nresearch, this review aims to discuss the efficacy of DCI and the role of emerging nutraceuticals for\nmanaging InsR in PCOS....
Loading....